Transplanted epithelial stem cells from a healthy eye repaired irreversible corneal injury and restored at least partial ...

Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Investors eyeing high-growth stocks should consider Corcept Therapeutics, TKO Group, and others with strong earnings ...

Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.

The Health and Human Services Department is reviewing contracts and moving to replace vaccine advisers in Robert F. Kennedy Jr.’s first few ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...

Under U.S. law, most patents are limited to a term of 20 years from the earliest nonprovisional filing date. However, Patent Term Adjustment (PTA) ...

The stock market has a way of proving the masses wrong. After all the chatter about the new administration’s potentially adverse impact on pharmaceutical stocks and related industries, the broader ...

The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.